OrthoPediatrics (NASDAQ:KIDS) Stock Price Down 6.2% – Should You Sell?

OrthoPediatrics Corp. (NASDAQ:KIDS)’s share price fell 6.2% on Tuesday . The company traded as low as $18.61 and last traded at $19.4410. Approximately 24,101 shares changed hands during trading, a decline of 85% from the average daily volume of 157,850 shares. The stock had previously closed at $20.72.

Analyst Ratings Changes

KIDS has been the subject of a number of recent analyst reports. Truist Financial set a $17.00 price objective on OrthoPediatrics in a research report on Friday, May 1st. TD Cowen reissued a “buy” rating on shares of OrthoPediatrics in a research note on Monday, June 15th. Weiss Ratings restated a “sell (e+)” rating on shares of OrthoPediatrics in a report on Tuesday, April 21st. Canaccord Genuity Group set a $25.00 price objective on shares of OrthoPediatrics in a research note on Friday, April 24th. Finally, BTIG Research reissued a “buy” rating and issued a $24.00 target price on shares of OrthoPediatrics in a research report on Friday, May 1st. Nine equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $24.44.

OrthoPediatrics Stock Down 6.0%

The stock has a fifty day moving average of $18.48 and a two-hundred day moving average of $17.64. The company has a quick ratio of 2.37, a current ratio of 5.21 and a debt-to-equity ratio of 0.29. The stock has a market cap of $499.99 million, a price-to-earnings ratio of -11.65 and a beta of 0.99.

OrthoPediatrics (NASDAQ:KIDS) last announced its quarterly earnings results on Thursday, April 30th. The company reported ($0.42) EPS for the quarter, topping the consensus estimate of ($0.46) by $0.04. The company had revenue of $59.36 million during the quarter, compared to analyst estimates of $58.28 million. OrthoPediatrics had a negative return on equity of 7.01% and a negative net margin of 16.31%. As a group, analysts predict that OrthoPediatrics Corp. will post -1.13 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Wasatch Advisors LP grew its stake in OrthoPediatrics by 56.6% during the second quarter. Wasatch Advisors LP now owns 515,677 shares of the company’s stock worth $9,865,000 after buying an additional 186,357 shares during the period. Quantinno Capital Management LP purchased a new position in shares of OrthoPediatrics in the 1st quarter valued at $160,000. Waverly Advisors LLC acquired a new position in shares of OrthoPediatrics during the 1st quarter valued at $184,000. Granahan Investment Management LLC lifted its holdings in shares of OrthoPediatrics by 35.1% during the 1st quarter. Granahan Investment Management LLC now owns 896,741 shares of the company’s stock valued at $14,231,000 after acquiring an additional 232,760 shares in the last quarter. Finally, Sei Investments Co. boosted its position in OrthoPediatrics by 31.1% during the 1st quarter. Sei Investments Co. now owns 82,081 shares of the company’s stock worth $1,303,000 after purchasing an additional 19,489 shares during the period. 69.05% of the stock is owned by institutional investors and hedge funds.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.